On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
How has patient advocacy grown to become the driver of rare disease drug development? In today's episode of Biorasi's Few & Far Between podcast,...
Raising awareness for rare diseases, such as Angelman Syndrome, should not be something parents, patients, and advocates have to do alone. Today's episode of...
"What can I contribute that my doctor can't contribute? And that's a real 'a-ha' moment when we share with them how they're the experts...